WallStSmart

Amgen Inc (AMGN)vsCognizant Technology Solutions Corp Class A (CTSH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amgen Inc generates 74% more annual revenue ($36.75B vs $21.11B). AMGN leads profitability with a 21.0% profit margin vs 10.6%. CTSH appears more attractively valued with a PEG of 1.02. CTSH earns a higher WallStSmart Score of 71/100 (B).

AMGN

Strong Buy

70

out of 100

Grade: B-

Growth: 8.0Profit: 8.5Value: 10.0Quality: 5.0
Piotroski: 4/9

CTSH

Strong Buy

71

out of 100

Grade: B

Growth: 5.3Profit: 7.5Value: 10.0Quality: 5.5
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMGNUndervalued (+46.8%)

Margin of Safety

+46.8%

Fair Value

$665.50

Current Price

$353.93

$311.57 discount

UndervaluedFair: $665.50Overvalued
CTSHUndervalued (+63.1%)

Margin of Safety

+63.1%

Fair Value

$192.25

Current Price

$59.79

$132.46 discount

UndervaluedFair: $192.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMGN5 strengths · Avg: 9.6/10
Return on EquityProfitability
106.1%10/10

Every $100 of equity generates 106 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

EPS GrowthGrowth
112.1%10/10

Earnings expanding 112.1% YoY

Market CapQuality
$187.83B9/10

Large-cap with strong market position

Profit MarginProfitability
21.0%9/10

Keeps 21 of every $100 in revenue as profit

CTSH3 strengths · Avg: 8.0/10
P/E RatioValuation
13.1x8/10

Attractively priced relative to earnings

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

EPS GrowthGrowth
22.1%8/10

Earnings expanding 22.1% YoY

Areas to Watch

AMGN2 concerns · Avg: 3.0/10
PEG RatioValuation
2.334/10

Expensive relative to growth rate

Price/BookValuation
22.0x2/10

Trading at 22.0x book value

CTSH2 concerns · Avg: 3.5/10
Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AMGN

The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.

Bull Case : CTSH

The strongest argument for CTSH centers on P/E Ratio, Price/Book, EPS Growth. PEG of 1.02 suggests the stock is reasonably priced for its growth.

Bear Case : AMGN

The primary concerns for AMGN are PEG Ratio, Price/Book.

Bear Case : CTSH

The primary concerns for CTSH are Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

AMGN profiles as a mature stock while CTSH is a value play — different risk/reward profiles.

CTSH carries more volatility with a beta of 0.98 — expect wider price swings.

AMGN is growing revenue faster at 8.6% — sustainability is the question.

AMGN generates stronger free cash flow (961M), providing more financial flexibility.

Bottom Line

CTSH scores higher overall (71/100 vs 70/100). AMGN offers better value entry with a 46.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amgen Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

Visit Website →

Cognizant Technology Solutions Corp Class A

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Cognizant is an American multinational technology company that provides business consulting, information technology and outsourcing services. It is headquartered in Teaneck, New Jersey, United States.

Want to dig deeper into these stocks?